D. Shaw

发表

Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen

M. Dohlsten, L. Ohlsson, G. Forsberg, 2001, British Journal of Cancer.

Peptide mimics of a conformationally constrained protective epitopes of respiratory syncytial virus fusion protein.

D. Chargelegue, M. Steward, D. Shaw, 1997, Immunology letters.

The Role of Extracellular Spacer Regions in the Optimal Design of Chimeric Immune Receptors: Evaluation of Four Different scFvs and Antigens

P. Stern, K. Chester, R. Guest, 2005, Journal of immunotherapy.

Glycosylation and epitope mapping of the 5T4 glycoprotein oncofoetal antigen.

P. Stern, E. Hounsell, M. Davies, 2002, The Biochemical journal.

Retroviral coexpression of thymidylate synthase and dihydrofolate reductase confers fluoropyrimidine and antifolate resistance.

H. Spencer, D. Shaw, J. Moore, 1998, Biochemical and biophysical research communications.

Instruments for oral disease-intervention strategies: recombinant Lactobacillus casei expressing tetanus toxin fragment C for vaccination or myelin proteins for oral tolerance induction in multiple sclerosis.

P. Pouwels, J. Laman, R. Leer, 1999, Vaccine.

5T4 interacts with TIP-2/GIPC, a PDZ protein, with implications for metastasis.

P. Stern, A. Awan, S. Lyons, 2002, Biochemical and biophysical research communications.

Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancer.

P. Stern, M. Carroll, D. Shaw, 2002, The Biochemical journal.

Engineering the microflora to vaccinate the mucosa: serum immunoglobulin G responses and activated draining cervical lymph nodes following mucosal application of tetanus toxin fragment C‐expressing lactobacilli

R. Leer, P. Pouwels, D. Shaw, 2000, Immunology.

The induction of respiratory syncytial virus-specific cytotoxic T-cell responses following immunization with a synthetic peptide containing a fusion peptide linked to a cytotoxic T lymphocyte epitope.

M. Steward, D. Shaw, S. Hsu, 1995, Immunology.

Isolation of a high affinity scFv from a monoclonal antibody recognising the oncofoetal antigen 5T4.

P. Stern, M. Carroll, D. Shaw, 2000, Biochimica et biophysica acta.

Vaccine and antibody-directed T cell tumour immunotherapy.

P. Stern, D. Gilham, R. Hawkins, 2004, Biochimica et biophysica acta.

Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors.

P. Stern, M. Carroll, D. Shaw, 2002, Molecular cancer therapeutics.

CXCR4 Mediated Chemotaxis Is Regulated by 5T4 Oncofetal Glycoprotein in Mouse Embryonic Cells

Crispin J. Miller, G. Marinov, P. Stern, 2010, PloS one.

A Novel Strategy To Reduce the Immunogenicity of Biological Therapies

A. Compston, A. Coles, G. Hale, 2010, The Journal of Immunology.

Influence of the T-helper epitope on the titre and affinity of antibodies to B-cell epitopes after co-immunization.

C. Partidos, M. Steward, D. Shaw, 1993, Molecular immunology.

Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteins

Miles W Carroll, P. Stern, M. Carroll, 2002, Cancer Gene Therapy.

1099 A phase II study of ABR-214936 (anatumomab mafenatox) tumour targeted superantigen (TTS) therapy in patients with advanced renal cell carcinoma (RCC)

P. Stern, C. Garner, P. Patel, 2003 .

Drug-resistant variants of Escherichia coli thymidylate synthase: effects of substitutions at Pro-254.

L. Lebioda, W. Minor, F. Berger, 1999, Molecular pharmacology.

Heparin and heparan sulfate bind interleukin-10 and modulate its activity.

J R Arrand, S. Salek-Ardakani, D. Shaw, 2000, Blood.